Stent News and Research RSS Feed - Stent News and Research

A stent is a small mesh tube that’s used to treat narrowed or weakened arteries in the body.

You may have a stent placed in an artery as part of a procedure called angioplasty (AN-jee-oh-plas-tee). Angioplasty can restore blood flow through narrowed or blocked arteries. Stents help prevent arteries from becoming narrowed or blocked again in the months or years after treatment with angioplasty. You may also have a stent placed in a weakened artery to improve blood flow and to help prevent the artery from bursting.

Stents are usually made of metal mesh, but sometimes they’re made of fabric. Fabric stents, also called stent grafts, are used in larger arteries. Some stents are coated with medicines that are slowly and continuously released into the artery. These medicines help prevent the artery from becoming blocked again.
Lombard Medical exhibits Aorfix system at Critical Issues in Aortic Endografting symposium

Lombard Medical exhibits Aorfix system at Critical Issues in Aortic Endografting symposium

Lombard Medical, Inc, a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA), exhibited its Aorfix Endovascular stent graft system at the 18th international experts' symposium, Critical Issues in Aortic Endografting, in Malmö, Sweden on June 27-28, 2014. [More]

Lombard Medical showcases Aorfix Endovascular Stent Graft at SVS Annual Meeting

Lombard Medical, Inc., a medical device company focused on Endovascular Aortic Repair (EVAR) of abdominal aortic aneurysms (AAA), showcased its Aorfix Endovascular Stent Graft at the 2014 Society for Vascular Surgery Annual Meeting in Boston, June 5-7. [More]
Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Cook Medical introduces Zilver PTX Drug-Eluting Peripheral Stent in Canada

Cook Medical launched its Zilver PTX Drug-Eluting Peripheral Stent in Canada at the Canadian Interventional Radiology Association (CIRA) meeting in Montreal, Canada. It's the first drug-coated stent in Canada indicated to treat peripheral arterial disease (PAD) in the superficial femoral artery (SFA). [More]
STENTYS signs agreement to acquire assets of Cappella Peel Away

STENTYS signs agreement to acquire assets of Cappella Peel Away

STENTYS, a medical technology company commercializing in Europe the world's first and only Self-Apposing® Stent to treat acute myocardial infarction (AMI), today announced the signing of the acquisition agreement of Cappella Peel Away Inc. (Delaware, USA) and its assets relating to a novel stent delivery system. The acquisition is subject to closing conditions. [More]
Zilver® PTX® drug-eluting stent from Cook Medical receives positive one-year follow-up results

Zilver® PTX® drug-eluting stent from Cook Medical receives positive one-year follow-up results

One-year follow-up data from 907 Japanese patients who received the Zilver® PTX® drug-eluting stent showed positive results in keeping open the superficial femoral artery (SFA). The postmarket surveillance (PMS) study, designed to evaluate the stent’s performance in real-world patient use, was presented at the 2014 Euro PCR meeting. [More]
Scientists report that coating stents with vitamin C reduces implants' risks

Scientists report that coating stents with vitamin C reduces implants' risks

Every year, more than 1 million people in the U.S. who have suffered heart attacks or chest pain from blocked arteries have little mesh tubes called stents inserted into their blood vessels to prop them open. [More]
Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies presents DESSOLVE I and II trial data at EuroPCR conference

Micell Technologies, Inc. today announced that long-term clinical outcomes from its DESSOLVE I and II clinical trials were presented at the EuroPCR conference in Paris, France this week. [More]
Experts discuss potential advantages of bioresorbable vascular scaffolds at EuroPCR 2014

Experts discuss potential advantages of bioresorbable vascular scaffolds at EuroPCR 2014

At EuroPCR 2014 yesterday, experts discussed the development in evidence for bioresorbable vascular scaffolds, which represent an era of vascular restoration in interventional cardiology. [More]
BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK ProMRI ICD trial expansion achieves FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration (FDA) has approved a significant expansion of its ongoing ProMRI® trial. [More]
Cook Medical to exhibit augmented reality experiences at AUA meeting

Cook Medical to exhibit augmented reality experiences at AUA meeting

Cook Medical will exhibit augmented reality experiences, which is a technology used to simulate use of products, and host a skills challenge at their booth, #1617, at the annual American Urological Association meeting. [More]
BIOTRONIK's Entovis pacemaker system gets FDA approval

BIOTRONIK's Entovis pacemaker system gets FDA approval

BIOTRONIK, a leading manufacturer of cardiovascular medical devices, announced today that the Food and Drug Administration has granted approval for its Entovis pacemaker system with ProMRI technology. [More]
ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD provides update on corporate developments, reports Q1 2014 financial results

ARIAD Pharmaceuticals, Inc. today reported financial results for the first quarter of 2014, including revenue from sales of Iclusig® (ponatinib) and licensing agreements. The Company also provided an update on corporate developments. [More]
Concise analysis of global disposable gloves market

Concise analysis of global disposable gloves market

MRRBIZ includes new market research report "Disposable Gloves Market For Medical and Non-Medical (Food, Cleanroom, Industrial And Other) Applications - Global Industry Analysis, Size, Share, Growth, Trends And Forecast 2013 - 2019" to its large collection of research report. [More]
Study shows room for improvement in medical management of women with PAD

Study shows room for improvement in medical management of women with PAD

Women face greater limits on their lifestyle and have more severe symptoms as a result of peripheral artery disease (PAD), but minimally invasive procedures used to unclog arteries are just as successful as in men. [More]
Cardiac Catheterization Laboratory of Mount Sinai Heart receives highest "two-star" safety rating

Cardiac Catheterization Laboratory of Mount Sinai Heart receives highest "two-star" safety rating

The Cardiac Catheterization Laboratory of Mount Sinai Heart at The Mount Sinai Hospital has once again received the highest "two-star" safety rating from the New York State Department of Health for its percutaneous coronary interventions (PCI) overall and in non-emergency cases. [More]
InspireMD initiates Voluntary Field Action for MGuard Prime EPS stent dislodgements

InspireMD initiates Voluntary Field Action for MGuard Prime EPS stent dislodgements

InspireMD, Inc., a leader in embolic protection systems (EPS), today announced that it has initiated a Voluntary Field Action (VFA) following recent reports of MGuard Prime EPS stent dislodgements. [More]
RWJUH offers new alternative to open up blocked arteries

RWJUH offers new alternative to open up blocked arteries

Treatment options for high-risk heart patients with severely calcified coronary artery disease (CAD) have been limited for more than 20 years. Now, Robert Wood Johnson University Hospital offers a new alternative to open up blocked arteries. [More]
Abbott completes enrollment of 3 clinical trials to support approval of Absorb Bioresorbable Vascular Scaffold

Abbott completes enrollment of 3 clinical trials to support approval of Absorb Bioresorbable Vascular Scaffold

Abbott (NYSE: ABT) today announced it has completed enrollment of three clinical trials to support approvals of the company's revolutionary Absorb™ Bioresorbable Vascular Scaffold (BVS) in the United States, Japan and China. [More]

Santen announces Phase III results of sirolimus intravitreal injections in non-infectious posterior segment uveitis patients

Santen Inc., the U.S. subsidiary of global ophthalmic pharmaceutical company Santen Pharmaceutical Co., Ltd. (Osaka, Japan), today announced that SAKURA (Study Assessing double‐masKed Uveitis tReAtment) Study 1, the first of two Global Phase III studies evaluating intravitreal injections of sirolimus in patients with non-infectious posterior segment uveitis (NI-PSU), met its primary endpoint. [More]
Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Boston Scientific presents new data on cardiology-related clinical trials at ACC 2014

Reinforcing its position as a global leader in bringing new therapies to patients with heart and cardiovascular disease, Boston Scientific Corporation (NYSE: BSX) reported favorable results in studies related to cardiac resynchronization therapy (CRT), platinum chromium stent platforms and transcatheter aortic valve replacement (TAVR). [More]